74356-41-5Relevant academic research and scientific papers
Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability
Kinney, William A.,McDonnell, Mark E.,Zhong, Hua Marlon,Liu, Chaomin,Yang, Lanyi,Ling, Wei,Qian, Tao,Chen, Yu,Cai, Zhijie,Petkanas, Dean,Brenneman, Douglas E.
supporting information, p. 424 - 428 (2016/05/19)
Cannabidiol is the nonpsychoactive natural component of C. sativa that has been shown to be neuroprotective in multiple animal models. Our interest is to advance a therapeutic candidate for the orphan indication hepatic encephalopathy (HE). HE is a serious neurological disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol is effective in models of HE, it has limitations in terms of safety and oral bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and "drug likeness", while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability.
Metabolism of (-)-epigallocatechin gallate by rat intestinal flora
Takagaki, Akiko,Nanjo, Fumio
experimental part, p. 1313 - 1321 (2010/09/04)
Anaerobic metabolism of ( - )-epigallocatechin gallate (EGCg) by rat intestinal bacteria was investigated in vitro. First, intestinal bacteria which are capable of hydrolyzing EGCg to ( - )epigallocatechin (EGC) and gallic acid (2) were screened with 169 strains of enteric bacteria. As a result, Enterobacter aerogenes, Raoultella planticola, Klebsiella pneumoniae susp. pneumoniae, and Bifidobacterium longum subsp. infantis were found to hydrolyze EGCg. Subsequent steps of EGCg metabolism are degradation of EGC (1) by intestinal bacteria. Then, EGC was incubated with rat intestinal bacteria in 0.1 M phosphate buffer (pH 7.1) and the degradation products were analyzed with time by HPLC or LC-MS. Further, the products formed from EGC were isolated and identified by LC-MS and NMR analyses. The results revealed that EGC was converted first to 1-(3', 4', 5'-trihydroxyphenyl)-3-(2 , 4 , 6 -trihydroxyphenyl)propan-2-ol (3) by reductive cleavage between 1 and 2 positions of EGC, and subsequently metabolite 3 was converted to 1-(3', 5'-dihydroxyphenyl)-3-(2 , 4 , 6 -trihydroxyphenyl)propan-2-ol (4) followed by the conversion to 5-(3, 5-dihydroxyphenyl)-4-hydroxyvaleric acid (5) by decomposition of the phloroglucinol ring in metabolite 4. This degradation pathway was considered to be the major route of EGCg metabolism in the in vitro study, but two minor routes were also found. In addition to the in vitro experiments, metabolites 3, 4, 5, and 6 were detected as the metabolites after direct injection of EGC into rat cecum. When EGCg was administered orally to the rats, metabolites 4, 5, 6, 11, and 12 were found in the feces. Among the metabolites detected, metabolite 5 was dominant both in the cecal contents and feces. These findings suggested that the metabolic pathway of EGCg found in the in vitro study may be regarded as reflecting its metabolism in vivo.
Synthesis of Cannabinoids Carrying ω-Carboxy Substituents: The Cannabidiols, Cannabinol and Δ1- and Δ6-Tetrahydrocannabinols of this Series
Crombie, Leslie,Crombie, W. Mary L.,Tuchinda, Patoomratana
, p. 1255 - 1262 (2007/10/02)
A convenient synthesis of methyl 5-(3,5-dihydroxyphenyl)pentanoate adaptable for isotopic side-chain labelling is reported.Using acid-catalysed terpenylations involving (1S,4R)-(+)-trans-p-menthadienol, conditions for making (3R,4R)-o- and p-cannabidiols,
